Prime Medicine, Inc. APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition
Prime Medicine, Inc. (PRME) reported APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition of $338.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition · last filed 2026-08-06
- Prime Medicine, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2026-06-30 was $338.00K, a 71.57% increase year-over-year.
- Prime Medicine, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2025-06-30 was $197.00K.
- Prime Medicine, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2024-09-30 was $401.00K.
- Prime Medicine, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2024-03-31 was $436.00K.
- Prime Medicine, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for fiscal 2025 was $341.00K, a 59.26% decline from fiscal 2024.
- Prime Medicine, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for fiscal 2024 was $837.00K.
| Period end | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 12 month |
|---|---|---|
| 2026-06-30 | $338.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $341.00K 10-K · filed 2026-03-03 | |
| 2025-06-30 | $197.00K 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $837.00K 10-K · filed 2026-03-03 | |
| 2024-09-30 | $401.00K 10-Q · filed 2025-11-07 | |
| 2024-03-31 | $436.00K 10-Q · filed 2025-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |